DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation" drug pipelines to their offering.
The HNC pipeline has 340 products active across all stages of development. The range of mechanisms of action employed by these compounds is very diverse, especially in comparison with the existing market landscape, and matches the diversity of many of the other oncology indication pipelines. More pertinently, there is a large proportion of breakthrough innovation in this pipeline.
Despite risks associated with developing first-in-class products, they have still proven to be a highly desirable investment option. Indeed, the high level of deal-making activity within the head and neck cancer space is indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations to mitigate some of the risks associated with drug development, such as the high attrition rates exhibited by oncology indications.
Factors driving the pipeline size include the limited efficacy of current treatments for refractory patients and a lack of approved targeted therapies in the market landscape, facilitating the development of novel compounds. These factors have far-reaching strategic implications for all market participants, as it is likely that numerous first-in-class products, many of which are supported by promising preclinical data, will reach the market over the coming decade, potentially transforming the clinical and commercial landscape.
The HNC deals landscape is highly active, with a mean value for co-development deals of $496.6m between 2006 and 2016, which is above the 2015 industry average of $346.8m, and a mean value for licensing deals of $198.6m, which is also above the industry average of $198.6m. Most deals involved drugs with established targets.
Key Topics Covered:
1 Executive Summary
2 The Case for Innovation in the Head and Neck Cancer Market
3 Clinical and Commercial Landscape
4 Assessment of Pipeline Product Innovation
5 Signaling Network, Disease Causation and Innovation Alignment
6 First-in-Class Target Evaluation
7 Deals and Strategic Consolidations
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/c9cvkb/frontier_pharma